Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Potent Activity of an Anti-ICAM1 Antibody–Drug Conjugate against Multiple Myeloma
Daniel W. Sherbenou, Su Yang, Christopher R. Behrens, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 22, pp. 6028-6038
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Intercellular Adhesion Molecule 1: More than a Leukocyte Adhesion Molecule
Cameron D. Haydinger, Liam M. Ashander, Alwin Chun Rong Tan, et al.
Biology (2023) Vol. 12, Iss. 5, pp. 743-743
Open Access | Times Cited: 38
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis
Alexandra M. Poos, Nina Prokoph, Moritz J. Przybilla, et al.
Blood (2023) Vol. 142, Iss. 19, pp. 1633-1646
Open Access | Times Cited: 31
Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses
Yanping Yang, Jaclyn E. McCloskey, Huan Yang, et al.
Cancer Immunology Research (2021) Vol. 9, Iss. 10, pp. 1158-1174
Open Access | Times Cited: 47
Communication between bone marrow mesenchymal stem cells and multiple myeloma cells: Impact on disease progression
Daniel García‐Sánchez, Alberto González-González, Ana Alfonso-Fernández, et al.
World Journal of Stem Cells (2023) Vol. 15, Iss. 5, pp. 421-437
Open Access | Times Cited: 17
Antibody-drug Conjugate Targets, Drugs, and Linkers
Beverly A. Teicher, Joel Morris
Current Cancer Drug Targets (2022) Vol. 22, Iss. 6, pp. 463-529
Closed Access | Times Cited: 23
Molecular and immunological mechanisms of clonal evolution in multiple myeloma
Stefan Förster, Ramin Radpour, Adrian F. Ochsenbein
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
ICAM‐1 Is Overexpressed by Cancers and Negatively Impacts Antibody‐Based Therapies Including Antibody–Drug Conjugates
J. Bradford Kline, Luigi Grasso, Nicholas C. Nicolaides
European Journal of Immunology (2025) Vol. 55, Iss. 3
Closed Access
Control of Tumor Progression by Angiocrine Factors
Elisenda Alsina‐Sanchís, Ronja Mülfarth, Andreas Fischer
Cancers (2021) Vol. 13, Iss. 11, pp. 2610-2610
Open Access | Times Cited: 27
Molecules promoting circulating clusters of cancer cells suggest novel therapeutic targets for treatment of metastatic cancers
Julian M. Rozenberg, Anton Buzdin, Tharaa Mohammad, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Intercellular adhesion molecule-1 (ICAM-1): From molecular functions to clinical applications in cancer investigation
Wen‐Jing Qian, Jinshan Yan, Xiaoyu Gang, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 6, pp. 189187-189187
Closed Access | Times Cited: 4
Generation of high affinity ICAM-1-specific nanobodies and evaluation of their suitability for allergy treatment
Ines Zettl, Т. И. Иванова, Mohammed Zghaebi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 14
Antibody–Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?
Upasana Ray, Robert Z. Orlowski
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 590-590
Open Access | Times Cited: 6
Facts and Hopes in Multiple Myeloma Immunotherapy
Adam S. Sperling, Kenneth C. Anderson
Clinical Cancer Research (2021) Vol. 27, Iss. 16, pp. 4468-4477
Open Access | Times Cited: 14
Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM)
Ling Zhong, Peng Hao, Qian Zhang, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 9
CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma
Xiaocheng Chen, Oi Kwan Wong, Lauren T. Reiman, et al.
Molecular Cancer Therapeutics (2023) Vol. 23, Iss. 2, pp. 127-138
Closed Access | Times Cited: 5
CD46–ADC Reduces the Engraftment of Multiple Myeloma Patient-Derived Xenografts
Michael J. VanWyngarden, Zachary J. Walker, Su Yang, et al.
Cancers (2023) Vol. 15, Iss. 22, pp. 5335-5335
Open Access | Times Cited: 5
Boosting Immunity against Multiple Myeloma
Raquel Lopes, Bruna Velosa Ferreira, Joana Caetano, et al.
Cancers (2021) Vol. 13, Iss. 6, pp. 1221-1221
Open Access | Times Cited: 9
Cancer drug resistance in multiple myeloma
Fatih M. Uckun
Cancer Drug Resistance (2022)
Open Access | Times Cited: 6
Targeting CAM-DR and Mitochondrial Transfer for the Treatment of Multiple Myeloma
Rikio Suzuki, Daisuke Ogiya, Yoshiaki Ogawa, et al.
Current Oncology (2022) Vol. 29, Iss. 11, pp. 8529-8539
Open Access | Times Cited: 6
Therapeutic Targeting Tongue Squamous Cell Carcinoma via ICAM1 Antibody‐Drug Conjugates in Preclinical Models
L.B. Ma, Yan‐zhi Xu, Yuxuan Yang, et al.
Advanced Therapeutics (2024) Vol. 7, Iss. 8
Open Access
Targeting Caveolin‐1 in Multiple Myeloma Cells Enhances Chemotherapy and Natural Killer Cell‐Mediated Immunotherapy
Dewen Zhan, Zhimin Du, S Zhang, et al.
Advanced Science (2024)
Closed Access
Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
Waqqas Tai, Ahsan Wahab, Diana Franco, et al.
Antibodies (2022) Vol. 11, Iss. 2, pp. 22-22
Open Access | Times Cited: 1
Data from Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses
Yanping Yang, Jaclyn E. McCloskey, Huan Yang, et al.
(2023)
Open Access
Data from Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses
Yanping Yang, Jaclyn E. McCloskey, Huan Yang, et al.
(2023)
Open Access
Therapeutic Targeting Tongue Squamous Cell Carcinoma via ICAM1 Antibody-Drug Conjugates in Preclinical Models
Peng Guo, Letao Ma, Ye Lu, et al.
Research Square (Research Square) (2023)
Open Access
Page 1 - Next Page

Scroll to top